

# ESMO Sarcoma and Rare Cancers Congress 2026



📅 Thursday, March 12, 2026

🕒 11:30am - 11:35am CET

- Title: Phase 1 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined With Irinotecan (I) and Temozolomide (T) in Adolescents and Adults With Ewing Sarcoma
- Oral presentation
- Abstract number: 84MO
- Lead author: Rashmi Chugh
- Presenting author: Ana Sebio García

 [INBRX-109 in Ewing sarcoma Data Update Oral Presentation](#)

(1.3 MB)

<https://inhibrxbiosciences.investorroom.com/events-and-presentations?item=55>